Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MP470

Known as: HPK56, MP-470 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Background Amuvatinib (MP-470) is a multi-targeted kinase inhibitor with potent activity against c-Kit, synergistic with DNA… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
2013
2013
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Background: Amuvatinib is an oral multi-targeted TKI… Expand
2011
2011
3074 Background: Amuvatinib is an oral multi-targeted TKI which inhibits the mutant forms of c-kit, and PDGFRα. It also disrupts… Expand
2010
2010
Background: MP-470 is an orally bioavailable multi-targeted tyrosine kinase inhibitor specifically designed to be a potent… Expand
2009
2009
Abacavir sulfate/lamivudine, Adalimumab, AdCD40L, Adefovir, Adefovir dipivoxil, Ambrisentan, Amlodipine, Amlodipine besylate… Expand
2009
2009
(-)-Gossypol; Abacavir sulfate/lamivudine, ACAM-1000, ACE-011, Agomelatine, AGS-004, Alemtuzumab, Alvocidib hydrochloride, AMG… Expand